Reneo Pharmaceuticals, Inc. (RPHM)

NASDAQ: RPHM · IEX Real-Time Price · USD
3.48
+0.30 (9.43%)
Aug 19, 2022 4:30 PM EDT - Market closed
9.43%
Market Cap 85.12M
Revenue (ttm) n/a
Net Income (ttm) -48.69M
Shares Out 24.46M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 54,434
Open 3.25
Previous Close 3.18
Day's Range 3.02 - 3.58
52-Week Range 1.92 - 11.40
Beta n/a
Analysts Buy
Price Target 26.86 (+671.8%)
Earnings Date Aug 9, 2022

About RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered... [Read more...]

Industry Biotechnology
IPO Date Apr 9, 2021
Employees 29
Stock Exchange NASDAQ
Ticker Symbol RPHM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RPHM stock is "Buy." The 12-month stock price forecast is 26.86, which is an increase of 671.84% from the latest price.

Price Target
$26.86
(671.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for pa...

Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for pa...

Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study ...

IRVINE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for pa...

Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for pa...

Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results

IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for pat...

Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for p...

Reneo Pharmaceuticals Announces Senior Leadership Promotions

IRVINE, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for p...

Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference

IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for pa...

Reneo Pharmaceuticals Announces Changes to its Board of Directors

IRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for pa...

Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results

IRVINE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for pa...

Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer

IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for pa...

Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies

IRVINE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for p...

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for p...

Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies

Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction

SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patient...

Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients...

Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients...

Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today

Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM...

Other symbols: VECT

Two Biotechs Are Set to Start Trading Today

VectivBio Holding and Reneo Pharmaceuticals are making their market debuts on Nasdaq.

Other symbols: VECT

Reneo Pharmaceuticals Announces Pricing of Initial Public Offering

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, g...